FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804761773> ?p ?o ?g. }

• W2804761773 endingPage "885" @default.
• W2804761773 startingPage "875" @default.
• W2804761773 abstract "Empagliflozin is an SGLT-2 inhibitor (SGLT-2i) which belongs to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose independently from insulin, through an increase in glycosuria. In addition to decreasing cardiovascular morbidity and mortality, empagliflozin has nephroprotective properties in high cardiovascular risk patients with type 2 diabetes. Decreased hyperfiltration and shifting towards more favorable renal fuel energetics with improved renal oxygenation may explain some of these properties. With this study, we propose to explore the effects of empagliflozin on renal tissue oxygenation using blood oxygenation level-dependent magnetic resonance imaging (BOLD-MRI). This is a double-blind, randomized, placebo-controlled study examining the acute and chronic renal effects of empagliflozin 10 mg. The primary outcome is the effects of empagliflozin on renal tissue oxygenation as measured by BOLD-MRI. The secondary outcomes include the effects of empagliflozin on tubular function, 24 h blood pressure control, and the influence of body mass index (BMI) on the renal response to empagliflozin. Fifteen normal weight, 15 overweight, and 15 obese non-diabetic subjects (men and women) will be recruited. Each participant will undergo 24 h urine collections and blood pressure measurements on day − 1, followed by an investigation day at the study center with blood and urine sampling and renal BOLD-MRI measurements before and 180 min after the administration of 10 mg empagliflozin or placebo. This sequence of measurements will be repeated after 1 month of a daily empagliflozin or placebo intake. To investigate renal oxygenation, the renal cortical and medullary R2*, as a marker of oxygenation, will be assessed by BOLD-MRI under standardized hydration conditions: the higher R2*, the lower oxygenation. SGLT-2 inhibitors have a profound effect on renal physiology. This is an important study that will explore for the first time whether inhibiting SGLT-2 with empagliflozin in healthy volunteers affects renal tissue oxygenation as determined by BOLD-MRI. Boehringer Ingelheim Pharma GmbH & Co. ClinicalTrials.gov identifier, NCT03093103." @default.
• W2804761773 created "2018-06-01" @default.
• W2804761773 creator A5020940174 @default.
• W2804761773 creator A5047558641 @default.
• W2804761773 creator A5062937570 @default.
• W2804761773 creator A5070800289 @default.
• W2804761773 creator A5087946690 @default.
• W2804761773 date "2018-05-25" @default.
• W2804761773 modified "2023-10-18" @default.
• W2804761773 title "Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol" @default.
• W2804761773 cites W1957004156 @default.
• W2804761773 cites W1982628508 @default.
• W2804761773 cites W1990025047 @default.
• W2804761773 cites W1995879209 @default.
• W2804761773 cites W2015696027 @default.
• W2804761773 cites W2044034911 @default.
• W2804761773 cites W2044773944 @default.
• W2804761773 cites W2050984826 @default.
• W2804761773 cites W2056976690 @default.
• W2804761773 cites W2062615129 @default.
• W2804761773 cites W2065822870 @default.
• W2804761773 cites W2078959937 @default.
• W2804761773 cites W2093107775 @default.
• W2804761773 cites W2120922908 @default.
• W2804761773 cites W2146264128 @default.
• W2804761773 cites W2153336680 @default.
• W2804761773 cites W2169353041 @default.
• W2804761773 cites W2402599050 @default.
• W2804761773 cites W2416348735 @default.
• W2804761773 cites W2500767839 @default.
• W2804761773 cites W2591873133 @default.
• W2804761773 cites W2615684303 @default.
• W2804761773 cites W4236514815 @default.
• W2804761773 doi "https://doi.org/10.1007/s12325-018-0708-y" @default.
• W2804761773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6015115" @default.
• W2804761773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29802538" @default.
• W2804761773 hasPublicationYear "2018" @default.
• W2804761773 type Work @default.
• W2804761773 sameAs 2804761773 @default.
• W2804761773 citedByCount "11" @default.
• W2804761773 countsByYear W28047617732019 @default.
• W2804761773 countsByYear W28047617732020 @default.
• W2804761773 countsByYear W28047617732021 @default.
• W2804761773 countsByYear W28047617732022 @default.
• W2804761773 crossrefType "journal-article" @default.
• W2804761773 hasAuthorship W2804761773A5020940174 @default.
• W2804761773 hasAuthorship W2804761773A5047558641 @default.
• W2804761773 hasAuthorship W2804761773A5062937570 @default.
• W2804761773 hasAuthorship W2804761773A5070800289 @default.
• W2804761773 hasAuthorship W2804761773A5087946690 @default.
• W2804761773 hasBestOaLocation W28047617731 @default.
• W2804761773 hasConcept C126322002 @default.
• W2804761773 hasConcept C126894567 @default.
• W2804761773 hasConcept C134018914 @default.
• W2804761773 hasConcept C142724271 @default.
• W2804761773 hasConcept C159641895 @default.
• W2804761773 hasConcept C204787440 @default.
• W2804761773 hasConcept C27081682 @default.
• W2804761773 hasConcept C2775887513 @default.
• W2804761773 hasConcept C2777180221 @default.
• W2804761773 hasConcept C2781214132 @default.
• W2804761773 hasConcept C555293320 @default.
• W2804761773 hasConcept C71924100 @default.
• W2804761773 hasConcept C84393581 @default.
• W2804761773 hasConceptScore W2804761773C126322002 @default.
• W2804761773 hasConceptScore W2804761773C126894567 @default.
• W2804761773 hasConceptScore W2804761773C134018914 @default.
• W2804761773 hasConceptScore W2804761773C142724271 @default.
• W2804761773 hasConceptScore W2804761773C159641895 @default.
• W2804761773 hasConceptScore W2804761773C204787440 @default.
• W2804761773 hasConceptScore W2804761773C27081682 @default.
• W2804761773 hasConceptScore W2804761773C2775887513 @default.
• W2804761773 hasConceptScore W2804761773C2777180221 @default.
• W2804761773 hasConceptScore W2804761773C2781214132 @default.
• W2804761773 hasConceptScore W2804761773C555293320 @default.
• W2804761773 hasConceptScore W2804761773C71924100 @default.
• W2804761773 hasConceptScore W2804761773C84393581 @default.
• W2804761773 hasFunder F4320310441 @default.
• W2804761773 hasIssue "6" @default.
• W2804761773 hasLocation W28047617731 @default.
• W2804761773 hasLocation W28047617732 @default.
• W2804761773 hasLocation W28047617733 @default.
• W2804761773 hasLocation W28047617734 @default.
• W2804761773 hasOpenAccess W2804761773 @default.
• W2804761773 hasPrimaryLocation W28047617731 @default.
• W2804761773 hasRelatedWork W1883072153 @default.
• W2804761773 hasRelatedWork W2140167475 @default.
• W2804761773 hasRelatedWork W2142032747 @default.
• W2804761773 hasRelatedWork W2414612037 @default.
• W2804761773 hasRelatedWork W2566774342 @default.
• W2804761773 hasRelatedWork W2572160933 @default.
• W2804761773 hasRelatedWork W2807204184 @default.
• W2804761773 hasRelatedWork W2922053938 @default.
• W2804761773 hasRelatedWork W2944849091 @default.
• W2804761773 hasRelatedWork W4237238868 @default.
• W2804761773 hasVolume "35" @default.
• W2804761773 isParatext "false" @default.
• W2804761773 isRetracted "false" @default.

• next